Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse

Journal of Medicinal Chemistry

Volumn 56, Issue 11, 2013, Pages 4537-4550

  Vasiljevik, Tamara ^a   Franks, Lirit N ^b   Ford, Benjamin M ^b   Douglas, Justin T ^a   Prather, Paul L ^b   Fantegrossi, William E ^b   Prisinzano, Thomas E ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BUTYL 7 METHOXY 3 (NAPHTHALEN 1 YLMETHYL) 1H INDOLE; 1 BUTYL 7 METHOXY 3 (NAPHTHALEN 2 YL) 1H INDOLE; AMINOALKYLINDOLE DERIVATIVE; CANNABINOID 1 RECEPTOR ANTAGONIST; INDOLE DERIVATIVE; RIMONABANT; UNCLASSIFIED DRUG;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN;

ALCOHOLISM; ANIMALS; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CHO CELLS; CONDITIONING, CLASSICAL; CRICETINAE; CRICETULUS; DRUG DESIGN; DRUG INVERSE AGONISM; ETHANOL; HUMANS; INDOLES; LIGANDS; MICE; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; SELF ADMINISTRATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84879064644     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400268b     Document Type: Article

References (45)

1. Bryant, K. J.; Nelson, S.; Braithwaite, M. D.; Roach, D. Integrating HIV/AIDS and Alcohol Research; National Institute on Alcohol Abuse and Alcoholism: Bethesda, MD; http://pubs.niaaa.nih.gov/publications/arh333/167-178. htm.
2. DrugFacts: Understanding Drug Abuse and Addiction; National Institute on Drug Abuse: Bethesda, MD, November 2011; http://www.drugabuse.gov/publications/ drugfacts/understanding-drug-abuse-addiction#references.
3. The Economic Impact of Illicit Drug Use on American Society; United States Department of Justice Nation Drug Intelligence Center: Johnstown, PA, April 2011; http://www.justice.gov/archive/ndic/pubs44/44731/44731p.pdf.
4. Adhikari, B. K., J.; Malaraner, A.; Pechacek, T.; Vong, T. Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses-United States, 2000-2004 MMWR Wkly. Rep. 2008, 57, 1226-1228, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5745a3.htm.
5. Rehm, J.; Mathers, C.; Popova, S.; Thavorncharoensap, M.; Teerawattananon, Y.; Patra, J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders Lancet 2009, 373, 2223-2233
6. Rehm, J. R., R.; Rekve, D.; Mathers, C. Global Status Report on Alcohol and Health; World Health Organization: Geneva, 2011; http://www.who.int/ substance-abuse/publications/global-alcohol-report/msbgsruprofiles.pdf.
7. Heilig, M.; Egli, M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms Pharmacol. Ther. 2006, 111, 855-876 (Pubitemid 44118437)
8. Justinova, Z.; Panlilio, L. V.; Goldberg, S. R. Drug addiction Curr. Top. Behav. Neurosci. 2009, 1, 309-346
9. Basavarajappa, B. S.; Cooper, T. B.; Hungund, B. L. Chronic ethanol administration down-regulates cannabinoid receptors in mouse brain synaptic plasma membrane Brain Res. 1998, 793, 212-218 (Pubitemid 28294088)
10. Basavarajappa, B. S.; Hungund, B. L. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N - arachidonoylphosphatidylethanolamine in SK-N-SH cells J. Neurochem. 1999, 72, 522-528 (Pubitemid 29055213)
11. Hungund, B. L.; Szakall, I.; Adam, A.; Basavarajappa, B. S.; Vadasz, C. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens J. Neurosci. 2003, 84, 698-704 (Pubitemid 36176928)
12. Wang, L.; Liu, J.; Harvey-White, J.; Zimmer, A.; Kunos, G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 1393-1398 (Pubitemid 36184012)
13. Xi, Z. X.; Peng, X. Q.; Li, X.; Song, R.; Zhang, H. Y.; Liu, Q. R.; Yang, H. J.; Bi, G. H.; Li, J.; Gardner, E. L. Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice Nature Neurosci. 2011, 14, 1160-1166
14. Morales, M.; Bonci, A. Getting to the core of addiction: Hooking CB2 receptor into drug abuse? Nature Med. 2012, 18, 504-505
15. Van Gaal, L. F.; Rissanen, A. M.; Scheen, A. J.; Ziegler, O.; Rossner, S.; Group, R. I.-E. S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 2005, 365, 1389-1397 (Pubitemid 40523733)
16. Janero, D. R.; Makriyannis, A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis Expert Opin. Emerging Drugs 2009, 14, 43-65
17. Christensen, R.; Kristensen, P. K.; Bartels, E. M.; Bliddal, H.; Astrup, A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 2007, 370, 1706-1713 (Pubitemid 350100788)
18. Janero, D. R. Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists Expert Opin. Emerging Drugs 2012, 17, 17-29
19. Sink, K. S.; McLaughlin, P. J.; Wood, J. A.; Brown, C.; Fan, P.; Vemuri, V. K.; Peng, Y.; Olszewska, T.; Thakur, G. A.; Makriyannis, A.; Parker, L. A.; Salamone, J. D. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats Neuropsychopharmacology 2008, 33, 946-955 (Pubitemid 351252707)
20. McLaughlin, P. J. Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity Behav. Pharmacol. 2012, 23, 537-550
21. Seely, K. A.; Prather, P. L.; James, L. P.; Moran, J. H. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol. Interventions 2011, 11, 36-51
22. Rosenbaum, C. D.; Carreiro, S. P.; Babu, K. M. Here today, gone tomorrow...and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines J. Med. Toxicol. 2012, 8, 15-32
23. Wiley, J. L.; Compton, D. R.; Dai, D.; Lainton, J. A.; Phillips, M.; Huffman, J. W.; Martin, B. R. Structure-activity relationships of indole- and pyrrole-derived cannabinoids J. Pharmacol. Exp. Ther. 1998, 285, 995-1004 (Pubitemid 28277896)
24. Aung, M. M.; Griffin, G.; Huffman, J. W.; Wu, M.; Keel, C.; Yang, B.; Showalter, V. M.; Abood, M. E.; Martin, B. R. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding Drug Alcohol Depend. 2000, 60, 133-140 (Pubitemid 30625016)
25. Brents, L. K.; Gallus-Zawada, A.; Radominska-Pandya, A.; Vasiljevik, T.; Prisinzano, T. E.; Fantegrossi, W. E.; Moran, J. H.; Prather, P. L. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity Biochem. Pharmacol. 2012, 83, 952-961
26. Huffman, J. W.; Zengin, G.; Wu, M. J.; Lu, J.; Hynd, G.; Bushell, K.; Thompson, A. L.; Bushell, S.; Tartal, C.; Hurst, D. P.; Reggio, P. H.; Selley, D. E.; Cassidy, M. P.; Wiley, J. L.; Martin, B. R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists Bioorg. Med. Chem. 2005, 13, 89-112 (Pubitemid 39575695)
27. Prather, P. L.; Martin, N. A.; Breivogel, C. S.; Childers, S. R. Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies Mol. Pharmacol. 2000, 57, 1000-1010 (Pubitemid 30253385)
28. Shoemaker, J. L.; Joseph, B. K.; Ruckle, M. B.; Mayeux, P. R.; Prather, P. L. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors J. Pharmacol. Exp. Ther. 2005, 314, 868-875 (Pubitemid 41043873)
29. 50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
30. Martin, B. R.; Compton, D. R.; Thomas, B. F.; Prescott, W. R.; Little, P. J.; Razdan, R. K.; Johnson, M. R.; Melvin, L. S.; Mechoulam, R.; Ward, S. J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs Pharmacol., Biochem. Behav. 1991, 40, 471-478
31. Compton, D. R.; Johnson, M. R.; Melvin, L. S.; Martin, B. R. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents J. Pharmacol. Exp. Ther. 1992, 260, 201-209
32. Keane, B.; Leonard, B. E. Rodent models of alcoholism: a review Alcohol Alcohol. 1989, 24, 299-309 (Pubitemid 19226146)
33. Cunningham, C. L.; Fidler, T. L.; Hill, K. G. Animal models of alcohol's motivational effects Alcohol Res. Health 2000, 24, 85-92
34. Vinod, K. Y.; Yalamanchili, R.; Thanos, P. K.; Vadasz, C.; Cooper, T. B.; Volkow, N. D.; Hungund, B. L. Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice Synapse 2008, 62, 574-581 (Pubitemid 351951295)
35. Ravinet Trillou, C.; Arnone, M.; Delgorge, C.; Gonalons, N.; Keane, P.; Maffrand, J. P.; Soubrie, P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice Am. J. Physiol.: Regul. Integr. Comp. Physiol. 2003, 284, R345-R353
36. Kirkham, T. C. Endogenous cannabinoids: a new target in the treatment of obesity Am. J. Physiol.: Regul. Integr. Comp. Physiol. 2003, 284, R343-R344
37. Biala, G.; Budzynska, B. Rimonabant attenuates sensitization, cross-sensitization and cross-reinstatement of place preference induced by nicotine and ethanol Pharmacol. Rep. 2010, 62, 797-807
38. Basavarajappa, B. S. The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism Mini-Rev. Med. Chem. 2007, 7, 769-779 (Pubitemid 47304939)
39. Parolaro, D.; Vigano, D.; Realini, N.; Rubino, T. Role of endocannabinoids in regulating drug dependence Neuropsychiatr. Dis. Treat. 2007, 3, 711-721
40. Maccioni, P.; Colombo, G.; Carai, M. A. Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data CNS Neurol. Disord. Drug Targets 2010, 9, 55-59
41. Qi, T.; Qiu, W.; Liu, Y.; Zhang, H.; Gao, X.; Liu, Y.; Lu, K.; Du, C.; Yu, G.; Zhu, D. Synthesis, Structures, and Properties of Disubstituted Heteroacenes on One Side Containing Both Pyrrole and Thiophene Rings J. Org. Chem. 2008, 73, 4638-4643 (Pubitemid 351842483)
42. Cai, J. P.; Chen, S. Q.; Chen, Y.; Chu, X.-J.; Goodnow, R. A., Jr.; Le, K.; Luk, K.-C.; Mischke, S. G.; Wovkulich, P. M. Thiazolyl-Benzimidazoles. U.S. Patent Appl. 20100160308, 2010; http://www.freepatentsonline.com/y2010/0160308. html.
43. Huang, Z.; Velazquez, C. A.; Abdellatif, K. R.; Chowdhury, M. A.; Reisz, J. A.; DuMond, J. F.; King, S. B.; Knaus, E. E. Ethanesulfohydroxamic acid ester prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs): synthesis, nitric oxide and nitroxyl release, cyclooxygenase inhibition, anti-inflammatory, and ulcerogenicity index studies J. Med. Chem. 2011, 54, 1356-1364
44. McBride, W. J.; Li, T. K. Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents Crit. Rev. Neurobiol. 1998, 12, 339-369 (Pubitemid 29073864)
45. Tzschentke, T. M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade Addict. Biol. 2007, 12, 227-462